{2-[1-(2-fluoroethyl)-1H-imidazol-4-yl]-ethyl}-carbamic acid tert-butyl ester | 941581-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: {2-[1-(2-fluoroethyl)-1H-imidazol-4-yl]-ethyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[2-[1-(2-fluoroethyl)imidazol-4-yl]ethyl]carbamate
• CAS: 941581-13-1
• 化学式: C₁₂H₂₀FN₃O₂
• 分子量: 257.308
• InChiKey: LNFMCTKSFHZDNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {2-[1-(2-fluoroethyl)-1H-imidazol-4-yl]-ethyl}-carbamic acid tert-butyl ester 在 N-氯代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 以40%的产率得到
  参考文献：
  名称：

  2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

  摘要：

  A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl) ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R potency and oral exposure. Analogs from both series, 16a and 17f, show in vivo activity comparable to 1 in our constitutively activated IGF-1R Sal tumor model. This may be the due to the improved protein binding in human and mouse serum for imidazole 16a and the excellent oral exposure of pyrazole 17f. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.049
• 作为产物：
  描述：

  2-(2-fluoro-ethyl)-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium bromide 、 叔丁醇 在 N,N-二异丙基乙胺 作用下， 反应 1.5h， 以39%的产率得到{2-[1-(2-fluoroethyl)-1H-imidazol-4-yl]-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Organic Compounds

  摘要：

  式I中R1、R2、R3、R4和X的自由或盐形式化合物，其含义如规范所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。

  公开号：

  US20080319033A1

文献信息

• Organic compounds
  申请人：Novartis AG

  公开号：US07754746B2

  公开（公告）日：2010-07-13

  Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and X have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1，R2，R3，R4和X的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了包含这些化合物的制药组合物以及制备这些化合物的过程。
• Thiazol-2-yl organic compounds
  申请人：Novartis AG

  公开号：EP2357179A1

  公开（公告）日：2011-08-17

  Compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4 and X have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  其中 R1、R2、R3、R4 和 X 的含义如说明书所示，游离或盐形式的式 (I) 化合物可用于治疗由磷脂酰肌醇 3- 激酶介导的疾病。还描述了含有这些化合物的药物组合物和制备这些化合物的工艺。
• US7754746B2
  申请人：——

  公开号：US7754746B2

  公开（公告）日：2010-07-13
• 2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924
  作者：Mark G. Saulnier、David B. Frennesson、Mark D. Wittman、Kurt Zimmermann、Upender Velaparthi、David R. Langley、Charles Struzynski、Xiaopeng Sang、Joan Carboni、Aixin Li、Ann Greer、Zheng Yang、Praveen Balimane、Marco Gottardis、Ricardo Attar、Dolatrai Vyas

  DOI：10.1016/j.bmcl.2008.01.049

  日期：2008.3

  A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl) ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R potency and oral exposure. Analogs from both series, 16a and 17f, show in vivo activity comparable to 1 in our constitutively activated IGF-1R Sal tumor model. This may be the due to the improved protein binding in human and mouse serum for imidazole 16a and the excellent oral exposure of pyrazole 17f. (C) 2008 Elsevier Ltd. All rights reserved.
• Organic Compounds
  申请人：Budd Emma

  公开号：US20080319033A1

  公开（公告）日：2008-12-25

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and X have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I中R1、R2、R3、R4和X的自由或盐形式化合物，其含义如规范所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。